Study on Ensartinib's Postoperative Use in Lung Cancer Published
Betta Pharmaceuticals' drug ensartinib was studied as a postoperative adjuvant therapy for lung cancer patients. The findings were published in The New England Journal of Medicine.
A study investigating the use of Betta Pharmaceuticals' drug ensartinib as postoperative adjuvant therapy for patients with ALK-positive non-small cell lung cancer (NSCLC) has been published online in The New England Journal of Medicine. The four-year ELEVATE study showed that ensartinib significantly improved the time to disease recurrence or death compared to standard chemotherapy.
The research included patients with stage IB–IIIB disease who underwent surgery. The results indicate ensartinib's potential to improve outcomes for individuals with resected ALK-positive NSCLC.
Betta Pharmaceuticals is a Chinese pharmaceutical company specializing in the development of oncology drugs. Ensartinib is a tyrosine kinase inhibitor designed to target specific cancer-driving proteins. Advances in targeted therapies are crucial for treating aggressive cancers.
The publication in a leading medical journal underscores the clinical significance of the findings and may inform future treatment guidelines for this patient population.